Grozdanova, Aleksandra
Preferred name
Grozdanova, Aleksandra
Official Name
Grozdanova, Aleksandra
Main Affiliation
Email
agrozdanova@ff.ukim.edu.mk
15 results
Now showing 1 - 10 of 15
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021)(Macedonian Academy of Sciences and Arts/Sciendo, 2021-04-23); ; Abstract The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive and specific therapeutic agents. Current therapeutic strategies are mainly focused on viral inhibition by antiviral drugs and hampering the exuberant immune response of the host by immunomodulatory drugs. In this review, we have studied the reports of the largest clinical trials intended to COVID-19 treatment published during the first year of the pandemics. In general, these results concentrate on seven therapeutic options: remdesivir, chloroguine/hydroxychloroquine, lopinavir-ritonavir combination, corticosteroids, tocilizumab, convalescent plasma and monoclonal antibodies. In line with the reviewed data, as of January 2021, most of the evidence support the use of remdesivir in hospitalized patients with moderate and severe forms of the disease and provide reliable data on the substantial beneficial effect of corticosteroids in patients requiring supplemental oxygen. Moreover, preliminary RECOVERY trial results have demonstrated the efficacy of tociluzumab in the treatment of critically ill patients. The reports presenting the outcomes of the other immune-based therapies under investigation are enthusiastically awaited. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Knowledge, opinions and attitudes of the general population in the Republic of N. Macedonia about vaccines and vaccination(Macedonian pharmaceutical association, 2022); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pharmacists` vaccine basic knowledge and attitudes in the RN Macedonia(Macedonian pharmaceutical association, 2022); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Community pharmacy practice in Montenegro in the period January-April 2020(Macedonian pharmaceutical association, 2022); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Use of tocilizumab for treatment of COVID-19 from off-label to extended indication(2022) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Role and activities of pharmacists in RN Macedonia at the beginning of COVID-19 pandemic: March-April 2020(Macedonian pharmaceutical association, 2022); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of the SARS-CoV-2 pandemic on routine immunization of the population in the Republic of North Macedonia(Macedonian Pharmaceutical Association, 2022-12-31); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Community pharmacists in RN Macedonia at the frontline of COVID-19 pandemic beginning: March-April 2020(Macedonian pharmaceutical association, 2022); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of Correlation Between the Pharmacogenetic Profiles of Risperidone Treated Psychiatry Patients with Plasma and Urine Concentration of Risperidone and its Active Moiety 9-OH Risperidone Determined with Optimized Bioanalytical LC Method(Walter de Gruyter GmbH, 2018-12-01); ; Atypical antipsychotic risperidone is widely used first-line monotherapy in schizophrenia and combined therapy in bipolar disorders. Therapeutic plasma concentrations of risperidone and its active moiety are directly influenced by genetic variations in metabolic CYP450 enzymes (CYP2D6 and CYP3A4/5) and transporter (ABCB1) protein and additional environmental factors. Since active metabolite 9-OH risperidone has a greater percentage of the pharmacologically active fraction and is equipotent to the parent drug risperidone, it is assumed that it contributes significantly to therapeutic and adverse effects. Unpredictable dose/concentration ratio, narrow therapeutic index, number of interactions, along with serious adverse reactions (ADR), raises the need for individualization of risperidone treatment and establishing of good therapeutic regime using TDM. A simple and reliable validated bioanalytical liquide-liquide extraction HPLC/UV method was applied for the simultaneous determination of risperidone and its active metabolite, 9-OH risperidone, in human plasma and urine of 52 hospitalized schizophrenia/bipolar disorder patients treated with risperidone as monotherapy and in polytherapy. All the patients were previously genotyped for CYP2D6 (EM=30, EM/IM=14, IM=4 IM/PM=1 and PM=3) and ABCB1 using Real-Time PCR methods with TaqMan SNP genotyping suitable assays according to the guidelines of the manufacturer (Life Technologies, USA).The influence of CYP2D6 phenotype on metabolic ratio MR (Ris/9-OHRis) in plasma (p=0.012) and in urine (p=0.048) was confirmed. Statistically significant correlation (R2=55.53%, Rho=0.844, p<0,0001) for MR in both plasma and urine indicates that urine may be utilized as appropriate media for initial CYP2D6 phenotype identification and selection of patients on risperidone treatment with high risk for ADR. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, THE INFLUENCE OF COVID-19 PANDEMIC ON THE VACCINATION OF THE POPULATION WITH THE INFLUENZA VACCINE IN THE REPUBLIC OF NORTH MACEDONIA(Institute of Knowledge Management, 2022-05-31);